The window Dallas has been waiting on is almost open.
Dallas-Fort Worth is one of the largest concierge medicine markets in the country. The corridor that runs from Park Cities through Preston Hollow up toward Plano and Frisco has been quietly building age-management and hormone-optimization protocols for two decades. Executive practices around Uptown, Knox-Henderson, and the Stemmons corridor see a steady stream of high-performing patients in their forties and fifties who are already running labs annually and treating the GH/IGF-1 axis as a domain worth understanding. What is changing now is the federal regulatory frame around growth-hormone-axis peptides, and the Dallas clinics that have been waiting on a clean legal lane are about to get one.
The short version: in 2023 the FDA placed several named peptides — including BPC-157, KPV, TB-500, MOTs-C, and others — into Category 2 of the 503A bulk substances list, which restricts but does not prohibit compounding. On April 16, 2026 a Federal Register notice reopened the nominations process. The Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to review the science and vote on whether those compounds move into Category 1 (clearly compoundable under 503A) or stay in Category 2. Whatever the committee decides, the Dallas providwrs preparing for that meeting are about to be in a very different position than they were a year ago.
Texas itself has been steady. The Texas State Board of Pharmacy permits 503A compounding for individual patient prescriptions, and the Texas Medical Board has consistently treated bioidentical hormone work and peptide therapy as practice-of-medicine questions for the physician-patient relationship. That is one reason the Dallas longevity and endocrinology practices have continued to work with licensed compounding pharmacies throughout the Category 2 period. Find Peptide Clinics exists to make that legitimate, licensed lane easy to find — and to make the gray-market storefronts easy to avoid.